Literature DB >> 19401450

Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.

Eric P Rahrmann1, Lara S Collier, Todd P Knutson, Meghan E Doyal, Sheri L Kuslak, Laura E Green, Rita L Malinowski, Laura Roethe, Keiko Akagi, Michelle Waknitz, Wei Huang, David A Largaespada, Paul C Marker.   

Abstract

Retroviral and transposon-based mutagenesis screens in mice have been useful for identifying candidate cancer genes for some tumor types. However, many of the organs that exhibit the highest cancer rates in humans, including the prostate, have not previously been amenable to these approaches. This study shows for the first time that the Sleeping Beauty transposon system can be used to identify candidate prostate cancer genes in mice. Somatic mobilization of a mutagenic transposon resulted in focal epithelial proliferation and hyperplasia in the prostate. Efficient methods were established to identify transposon insertion sites in these lesions, and analysis of transposon insertions identified candidate prostate cancer genes at common insertion sites, including Pde4d. PDE4D was also overexpressed in human prostate cancer patient samples and cell lines, and changes in PDE4D mRNA isoform expression were observed in human prostate cancers. Furthermore, knockdown of PDE4D reduced the growth and migration of prostate cancer cells in vitro, and knockdown of PDE4D reduced the growth and proliferation rate of prostate cancer xenografts in vivo. These data indicate that PDE4D functions as a proliferation promoting factor in prostate cancer, and the Sleeping Beauty transposon system is a useful tool for identifying candidate prostate cancer genes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401450      PMCID: PMC2710962          DOI: 10.1158/0008-5472.CAN-08-3901

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.

Authors:  Wito Richter; S-L Catherine Jin; Marco Conti
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

Review 3.  Retroviral insertional mutagenesis as a strategy to identify cancer genes.

Authors:  J Jonkers; A Berns
Journal:  Biochim Biophys Acta       Date:  1996-05-16

4.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

Authors:  Adam J Dupuy; Keiko Akagi; David A Largaespada; Neal G Copeland; Nancy A Jenkins
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

5.  High incidence of proviral integrations in the Hoxa locus in a new model of E2a-PBX1-induced B-cell leukemia.

Authors:  Janet Bijl; Martin Sauvageau; Alexander Thompson; Guy Sauvageau
Journal:  Genes Dev       Date:  2005-01-15       Impact factor: 11.361

6.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.

Authors:  Ekatherine Asatiani; Wen-Xin Huang; Antai Wang; Elizabeth Rodriguez Ortner; Luciane R Cavalli; Bassem R Haddad; Edward P Gelmann
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

Review 8.  MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.

Authors:  R Callahan; G H Smith
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

9.  Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.

Authors:  Miranda Warren; Matthew Twohig; Thomas Pier; Jens Eickhoff; Chen-Yong Lin; David Jarrard; Wei Huang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

10.  Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.

Authors:  D H Kim; A Lerner
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

View more
  47 in total

1.  Unexpectedly high copy number of random integration but low frequency of persistent expression of the Sleeping Beauty transposase after trans delivery in primary human T cells.

Authors:  Xin Huang; Kari Haley; Marianna Wong; Hongfeng Guo; Changming Lu; Andrew Wilber; Xianzheng Zhou
Journal:  Hum Gene Ther       Date:  2010-10-19       Impact factor: 5.695

Review 2.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

3.  Duration of expression and activity of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery.

Authors:  Jason B Bell; Elena L Aronovich; Jeffrey M Schreifels; Thomas C Beadnell; Perry B Hackett
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

Review 4.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

5.  New Prognostic Markers: The Pathway from Research to Clinical Practice.

Authors:  Caroline Savage; Andrew J Vickers
Journal:  Grand rounds Urol       Date:  2009-08

6.  Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.

Authors:  De-Chen Lin; Liang Xu; Ling-Wen Ding; Arjun Sharma; Li-Zhen Liu; Henry Yang; Patrick Tan; Jay Vadgama; Beth Y Karlan; Jenny Lester; Nicole Urban; Michèl Schummer; Ngan Doan; Jonathan W Said; Hongmao Sun; Martin Walsh; Craig J Thomas; Paresma Patel; Dong Yin; Daniel Chan; H Phillip Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

Review 7.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

Review 8.  Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.

Authors:  Amy P Chiu; Barbara R Tschida; Lilian H Lo; Branden S Moriarity; Dewi K Rowlands; David A Largaespada; Vincent W Keng
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Transcription Factor Trps1 Promotes Tubular Cell Proliferation after Ischemia-Reperfusion Injury through cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D and AKT.

Authors:  Yang Ju-Rong; Chen Ke-Hong; Huang Kun; Fu Bi-Qiong; Lin Li-Rong; Zhang Jian-Guo; Li Kai-Long; He Ya-Ni
Journal:  J Am Soc Nephrol       Date:  2016-07-27       Impact factor: 10.121

10.  Remobilization of Tol2 transposons in Xenopus tropicalis.

Authors:  Donald A Yergeau; Clair M Kelley; Emin Kuliyev; Haiqing Zhu; Amy K Sater; Dan E Wells; Paul E Mead
Journal:  BMC Dev Biol       Date:  2010-01-22       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.